Cengiz Özemli
Akademisyen
- Thread Author
- #1
## AstraZeneca and Multiply Labs Launch Collaboration in Cell Therapy Robotics
A new collaboration has been initiated between AstraZeneca and Multiply Labs to utilize modular robotic systems to enhance efficiency in cell therapy manufacturing.
This partnership aims to evaluate Multiply Labs' GMP-compliant and modular robotic arms in high-capacity production environments. The collaboration seeks to combine AstraZeneca's clinical and manufacturing expertise with Multiply Labs' automation technology to develop new commercial-scale solutions for robot-assisted cell therapy manufacturing.
### Cell Therapy Robotic Modules
Multiply Labs' robotic platform consists of robotic arms that slide between modules to perform cell therapy manufacturing tasks in parallel. This system increases both efficiency and process speed in production.
### Cell Therapies and Manufacturing Challenges
Cell therapies are complex and personalized treatment methods where immune cells are genetically modified and returned to the patient. Throughout the treatment process, all stages must be meticulously monitored and executed in accordance with GMP and clinical standards.
Autologous cell therapy, the process of genetically modifying and expanding a patient's own cells, is highly costly. On the other hand, allogeneic cell therapy involves genetically modifying and mass-producing healthy donor cells, a method that reduces cost but carries risks such as immune rejection.
Both types of treatment require high accuracy and precision in laboratory procedures. Furthermore, scaling up and increasing the efficiency of cell therapy manufacturing are among the priority needs in the industry today.
### Multiply Labs Robotic System
Multiply Labs' modular robotic system allows users to create their desired process in cell therapy manufacturing by selecting specific modules. The modules contain specialized instruments for specific tasks such as cell expansion, incubation, maintaining sterile conditions, and reagent mixing.
This parallel modular structure enables robotic arms to move quickly between modules, optimizing the production flow. This supports increased productivity and output through speed, precision, and instrument accessibility.
### Collaboration and Future Vision
Multiply Labs began a joint effort with the Stanford GMP Laboratory in early 2024 to compare manual and automated cell therapy processes. This collaboration aims to demonstrate the benefits of automation to the industry.
The latest agreement between AstraZeneca and Multiply Labs involves testing robot-assisted cell therapy manufacturing at commercial scales. Multiply Labs' robotic arms and technology, combined with AstraZeneca's clinical expertise, aim to create a high-capacity, efficient, and fully compliant production infrastructure.
In summary, this collaboration is seen as a significant step towards the widespread adoption of robotic automation in cell therapy and the optimization of manufacturing processes at an industrial scale.
